MarketBeat
14 May 2026, 08:06 UTC · 22w ago
Verdict
Headline takes no side. We score ANNX +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 90% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Annexon's base case expectation is success on the primary endpoint of best-corrected visual acuity for its 659-patient Phase 3 geographic atrophy study, with top-line data expected in Q4.
More positive than 99% of claims this week
Annexon expects to file for U.S. approval of its Guillain-Barré syndrome therapy this year, despite the challenge of demonstrating effectiveness and generalizability to Western patients since pivotal studies were conducted outside the U.S.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 98% of claims this week
Annexon has already filed for European approval of its Guillain-Barré syndrome therapy based on a pivotal Phase 3 study showing improvement within one week and durability to six months.
More positive than 94% of claims this week
Annexon believes demonstrating vision preservation in Phase 3 could drive significant market uptake in earlier-stage geographic atrophy, as 80% of GA patients currently go untreated and up to half of treated patients discontinue existing therapies within a year.
More positive than 89% of claims this week
Which stocks this story touches
More positive than 90% of ticker scores this week
The company provided positive updates on Phase 3 data expectations for geographic atrophy and regulatory filings for Guillain-Barré syndrome.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
19h ago
−37.4%
Price is moving against the score
$3.41 vs $5.45 close before publication (May 13) · not market-adjusted
ANNX chart →
